title: A report from the 47th European Association for the Study of Diabetes annual meeting (September 12-16, 2011 - Lisbon, Portugal).
abstract: Walking the streets in Lisbon is not a matter of inertia, at least when going uphill through the small streets crowding the slopes around the Alfama and Bairro Alto neighborhoods. However, when treating diabetes, clinical inertia seems to be the rule, despite the availability of effective therapies and recommendations for early insulin replacement to improve glucose control and prevent diabetes complications. This was further confirmed in the SOLVE study presented during this year's European Association for the Study of Diabetes (EASD) meeting (Khunti, K. et al., Abst 377), highlighting the importance of understanding healthcare habits to implement policies aimed at appropriate treatment intensification and even initiation to achieve earlier glycemic control of type 2 diabetes. However, preventing type 2 diabetes is crucial, in which regard physical activity has been repeatedly reported to reduce the risk of acquiring type 2 diabetes, and does so independently of its impact on general and abdominal adiposity (Ekelund, U. et al., Abst 225), resulting in a clearly cost-effective option to avoid the disease and the need for treatments. Although physical activity improves fitness but not glycemic control in type 1 diabetes (Valletta, J.J. et al., Abst 602), this is feasible through educational campaigns aimed at improving eating habits, routine physical exercise and healthy lifestyles, which, as demonstrated among students in Mexico, reduced the incidence of obesity and overweight (Martínez, M.E., Abst 858). Nevertheless, type 2 diabetes is a reality that is actually on the rise and requires treatments aimed at maintaining glycemic control, thus avoiding diabetic complications, while minimizing the risk of hypoglycemia and its consequences. Reducing hemoglobin A1c levels below 7%, as recommended by most guidelines for the treatment of diabetes, was confirmed to be associated with a reduced risk of death and diabetes-related morbidity in a population study in patients with type 2 diabetes (Skriver, M.V. et al., Abst 54). Hence, treatments are critical for achieving glycemic goals and preventing undue deaths. A wide range of therapies are currently available, but new drugs are under research that may potentially improve outcomes with a lower risk for adverse events, or may offer efficacy in patients currently not at goal because of insufficient efficacy of the drugs they are receiving, or because the doses they would require would cause excessive toxicity or an undue risk for hypoglycemia. New findings with currently available drugs and drugs in research that were reported during this year's EASD meeting in the beautiful city of Lisbon are summarized in the following report.
authors.affiliation: Medical Department, Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D001645:Biguanides / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000628:therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D020536:Enzyme Activators / Q000627:therapeutic use; D005941:Glucokinase / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D050608:Sodium-Phosphate Cotransporter Proteins / Q000037:antagonists & inhibitors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D001645:Biguanides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D020536:Enzyme Activators; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D026902:Potassium Channel Blockers; D050608:Sodium-Phosphate Cotransporter Proteins; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D005941:Glucokinase